For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

In recent decades, there has been a significant amount of research into breast cancer, with
some important breakthroughs in the treatment of both primary and metastatic breast …

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that plays an
oncogenic role in breast, gastric and other solid tumors. However, anti-HER2 therapies are …

Antibody–drug conjugates (ADC) are designed to be stable in circulation and to release
potent cytotoxic drugs intracellularly following antigen-specific binding, uptake, and …

Amplification and overexpression of HER2 (human epidermal growth factor receptor 2), an
ErbB2 receptor tyrosine kinase, have been implicated in human cancer and metastasis. A …

Antibody–drug conjugates (ADC) are emerging as powerful cancer treatments that combine
antibody-mediated tumor targeting with the potent cytotoxic activity of toxins. We recently …

Monoclonal antibodies have become an important class of therapeutics in the last 30 years.
Because the mechanism of action of therapeutic antibodies is intimately linked to their …

Introduction: Antibody drug conjugates now make up a significant fraction of biopharma's
oncology pipeline due to great advances in the understanding of the three key components …

Aptamers provide a potential source of alternative targeting molecules for existing antibody
diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the …

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory
bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being …